Zobrazeno 1 - 10
of 119
pro vyhledávání: '"Gregory B Lesinski"'
Autor:
Mark Yarchoan, Skylar Woolman, Lauren Dennison, Gregory B. Lesinski, Kayla Cruz, James M. Leatherman, Nilofer S. Azad, Elizabeth M. Jaffee, Aditya Mohan, Amanda Ruggieri
Publikováno v:
Cancer Immunol Res
MEK inhibition (MEKi) is proposed to enhance antitumor immunity but has demonstrated mixed results as an immunomodulatory strategy in human clinical trials. MEKi exerts direct immunomodulatory effects on tumor cells and tumor-infiltrating lymphocytes
Autor:
Kristen K. Ciombor, Yoanna Pumpalova, Christina Wu, Tanios Bekaii-Saab, Mohamad Bassam Sonbol, Jordan Berlin, Gregory B. Lesinski, Zhengjia Chen, Bassel F. El-Rayes, Ibrahim Halil Sahin, Amber Draper, Subir Goyal, Sigurdis Haraldsdottir, Satya Das, Daniel H. Ahn
Publikováno v:
Oncologist
Background Immune checkpoint inhibitor (ICI) therapy is highly effective in metastatic mismatch repair-deficient (MMR-D) colorectal cancer (CRC). In this study, we evaluated molecular and clinical predictors of ICI response in MMR-D CRC. Materials an
Autor:
Edmund K. Waller, Maria Cardenas, Gregory B. Lesinski, Bassel F. El-Rayes, Jingru Zhu, Mohammad Y. Zaidi, Shuhua Wang, Brian S. Robinson, Michael B. Ware, Susan N. Thomas, Yuan Liu, Tenzin Passang Fnu, Shanmuganathan Chandrakasan, Sruthi Ravindranathan, Jian-Ming Li, Alan B. Frey, Rohan K. Dhamsania, Sanjeev Gumber, Anish Majumdar, Haydn T. Kissick
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPaucity of T cells in the immune privileged tumor microenvironment (TME) of pancreatic ductal adenocarcinoma (PDAC) is a major reason that PDAC is refractory to immune checkpoint blockade.1 In this study, we show that human PDAC tumors over
Autor:
Juan M. Sarmiento, Shishir K. Maithel, Cameron Herting, Gregory B. Lesinski, Chrystal M. Paulos, Maggie Phillips, Megan M. Wyatt, Thomas A. Mace, Michael B. Ware, Bassel F. El-Rayes
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss Suppl 2 (2021)
BackgroundPancreatic ductal adenocarcinoma (PDAC) is refractory to immunotherapy due in part to cellular cross-talk with cancer associated fibroblasts (CAFs). These interactions shape the microenvironment in a manner that is profoundly immunosuppress
Autor:
Gregory B. Lesinski, Ibrahim Halil Sahin, Sujata R. Kane, Clifford J. Gunthel, Jessica Guadagno, Edith Brutcher, Christina Wu, Bassel F. El-Rayes, Katherine Emilie Rhoades Smith
Publikováno v:
JCO Oncology Practice. 16:319-325
Recent studies have identified durable responses with the use of immune checkpoint inhibitors in patients with mismatch repair–deficient (MMR-D)/microsatellite instability–high (MSI-H) metastatic colorectal cancer (CRC). The dramatic improvement
Autor:
Mehmet Akce, Gregory B. Lesinski, Christina Wu, Olatunji B. Alese, Bassel F. El-Rayes, Ibrahim Halil Sahin, Walid L. Shaib
Publikováno v:
British Journal of Cancer
Metastatic colorectal cancer (CRC) with a mismatch repair-deficiency (MMR-D)/microsatellite instability-high (MSI-H) phenotype carries unique characteristics such as increased tumour mutational burden and tumour-infiltrating lymphocytes. Studies have
Autor:
Michael Ware, Christopher McQuinn, Mohommad Zaidi, Hannah Knochelmann, Brian Robinson, Cameron Herting, Thomas Mace, Zhengjia Chen, Chao Zhang, Matthew Farren, Amanda Ruggieri, Jacob Bowers, Reena Shakya, Alton Farris III, Greg Young, William Carson III, Bassel El-Rayes, Chrystal Paulos, Gregory B. Lesinski
Pancreatic ductal adenocarcinoma (PDAC) is exceptionally resistant to immune checkpoint inhibition (ICI). We previously reported that elevated systemic interleukin-6 (IL-6) and increased numbers of T cells positive for circulating cytotoxic T-lymphoc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31d2e3ec24546872434c9300ce2d0736
https://doi.org/10.21203/rs.3.rs-599225/v1
https://doi.org/10.21203/rs.3.rs-599225/v1
Autor:
Katerina Mary Zakka, Bassel F. El-Rayes, Gregory B. Lesinski, Jerome C. Landry, Ganji Purnachandra Nagaraju, Walid L. Shaib
Publikováno v:
International Journal of Cancer. 145:1529-1537
Resistance of pancreatic ductal adenocarcinoma (PDAC) to radiotherapy and chemotherapy represents a significant clinical issue. Although the mechanisms of resistance are multi-faceted, client proteins of heat shock protein 90 (HSP90) such as hypoxia
Autor:
Anne M. Noonan, Gregory B. Lesinski, Mitchell L. Ramsey, Mary Dillhoff, Priyani V. Rajasekera, Tanios Bekaii-Saab, P. Mark Bloomston, Matthew R. Farren, Darwin L. Conwell, Somashekar G. Krishna, Carl Schmidt, Alice Hinton, Zobeida Cruz-Monserrate, Erin E. Talbert, Andrei Manilchuk, Timothy M. Pawlik, Daniel H. Ahn, Denis C. Guttridge, Niharika Badi, Phil A. Hart, Thomas A. Mace
Publikováno v:
Pancreatology. 19:80-87
BACKGROUND: Cachexia is a wasting syndrome characterized by involuntary loss of >5% body weight due to depletion of adipose and skeletal muscle mass. In cancer, the pro-inflammatory cytokine interleukin-6 (IL-6) is considered a mediator of cachexia a
Autor:
Wanqi Chen, Dong M. Shin, Sreenivas Nannapaneni, Andreas Wieland, Rafi Ahmed, Gregory B. Lesinski, Mihir R. Patel, Christopher C. Griffith, Zhengjia Chen, Zhuo Georgia Chen, Nabil F. Saba
Publikováno v:
Head and Neck Pathology. 13:304-312
This study addresses the hypothesis that IL-6/STAT3 signaling is of clinical relevance in oropharyngeal squamous cell carcinoma (OPSCC). We evaluated relationships between key components of this pathway in tumors from a unique cohort of n = 59 fully